undamentalytics Newsletter
Sign in

Aytu Biopharma, Inc cash flow statement

In fiscal 2026, Aytu Biopharma, Inc's operations generated $3.3m of cash; it spent $29,000 on capital projects, leaving free cash flow of $3.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Cash from operations−6−7−11−14−16−14−28−26−29−5−1−23
Depreciation and amortisation00143369109854
Stock-based pay0113111456211
Capital spending000000020—000
Free cash flow−6−7−11−14−16−14−28−28−29—−2−23
Free cash flow after stock pay−6−8−12−16−17−15−29−32−34—−4−33
Shares issued—001121566451216———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AQST vs AYTUAYTU vs DERMAYTU vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aytu Biopharma, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aytu Biopharma, Inc.